Plus   Neg

Cara Therapeutics Inc. (CARA) Has Broken Out To A New High On Study Results

Cara Therapeutics Inc. (CARA) announced Wednesday morning that its Phase 2/3 trial of I.V. CR845 in patients undergoing abdominal surgeries demonstrated statistically significant reductions in pain intensity compared to placebo.

Cara Therapeutics has gapped open sharply higher this morning and is now up 5.02 at $21.46 on above average volume. The stock has broken out past resistance and has set a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT